Modality
Bispecific Ab
MOA
RAS(ON)i
Target
DLL3
Pathway
Tau
Heart FailureBladder CaCervical Ca
Development Pipeline
Preclinical
~Sep 2011
→ ~Dec 2012
Phase 1
~Mar 2013
→ ~Jun 2014
Phase 2
~Sep 2014
→ ~Dec 2015
Phase 3
~Mar 2016
→ ~Jun 2017
NDA/BLA
Sep 2017
→ Aug 2031
NDA/BLACurrent
NCT06896724
1,773 pts·Bladder Ca
2017-09→2031-08·Active
1,773 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-08-135.4y awayPh3 Readout· Bladder Ca
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2031-08-13 · 5.4y away
Bladder Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06896724 | NDA/BLA | Bladder Ca | Active | 1773 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 |